Last reviewed · How we verify
Evaluation of an Antihypertensive Food Supplement Based on Aqueous Extract From Annona Muricata Sheets (AM-HTN)
The AM-HTN trial aim to investigate the effects of a tablet based on aqueous extracts of Annona muricata as add-on therapy in a hypertensive population. Patients with prehypertension or stage 1 hypertension confirmed, will be selected and assign in a single arm, non randomly, open label clinical trial. The group will receive in addition to their dietary measures, daily, one tablet of 796 mg of aqueous extracts of Annona muricata leaves. The objective of AM-HTN is to determine the antihypertensive and metabolic effects of AM tablets in a population of African hypertensives. Blood pressure profile, lipid profile, serum creatinine and transaminases profiles will be recorded and analysed at baseline and two months following enrolment.
Details
| Lead sponsor | Yaounde Central Hospital |
|---|---|
| Phase | PHASE2, PHASE3 |
| Status | COMPLETED |
| Enrolment | 21 |
| Start date | Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Jun 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Hypertension
Interventions
- Annona muricata
Countries
Cameroon